Ovarian endometrial cancer

Summary

Ovarian endometrial cancer (MONDO:0003812) is a cancer and 4 clinical trials. Top therapeutic interventions include topotecan hydrochloride. A subtype of endometrioid tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian endometrial cancer
Mondo ID	MONDO:0003812
DOID	DOID:6212
NCIT	C40051
UMLS	C1518231
MedGen	276545
GARD	0023680
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: endometrioid tumor of ovary · endometrioid tumour of ovary · malignant ovarian endometrioid tumor · malignant ovarian endometrioid tumour · ovary endometrioid tumor · ovary endometrioid tumour · ovary female reproductive endometrioid cancer

Disease family

This is a subtype of endometrioid tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › endometrioid tumor › ovarian endometrial cancer

Subtypes (2): ovarian carcinosarcoma, ovarian endometrioid adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04034927	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
NCT02569957	PHASE2	TERMINATED	Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT00899093	Not specified	TERMINATED	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TOPOTECAN HYDROCHLORIDE	4	1